<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02469545</url>
  </required_header>
  <id_info>
    <org_study_id>133-47818</org_study_id>
    <nct_id>NCT02469545</nct_id>
  </id_info>
  <brief_title>Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment</brief_title>
  <official_title>Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Bialystok</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Bialystok</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the influence of supplementation of probiotic
      Lactobacillus Plantarum 299V vs. placebo of probiotic during antidepressant monotherapy with
      SSRI (Selective Serotonin Reuptake Inhibitor) in patients with major depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For period of 8 weeks patient will receive probiotic Lactobacillus Plantarum 299V or its
      placebo as a supplementation of regular depression treatment with SSRI (Escitalopram or
      Sertraline). Psychometric and biochemical parameters will be monitored and evaluated. At day
      one, after 3 weeks (day 21) and after 8 weeks (day 56) of the study psychometric parameters
      will be measured such as Hamilton Depression Rating Scale, PSS-10 Scale, SCL-90 scale. At day
      one and after 8 weeks (day 56) of the study cognitive functions will be measured using: CVLT-
      California Verbal Learning Test, RFFT Ruff Figural Fluency Test, Stroop Test, Connecting
      Points Test (A and B), Attention and Perceptivity Test. At day one and after 8 weeks (day 56)
      of the study biochemical parameters will be measured such as: morning cortisol, pro and
      anti-inflammatory cytokines, tryptophan and its kynurenic pathway metabolites concentrations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of psychometric parameters - Change in Hamilton Depression Rating Scale from baseline at 3 weeks and 8 weeks of the study.</measure>
    <time_frame>At day one, after 3 weeks (day 21), after 8 weeks (day 56) of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of psychometric parameters - Change in Perceived Stress Scale (PSS-10) from baseline at 3 weeks and 8 weeks of the study.</measure>
    <time_frame>At day one, after 3 weeks (day 21), after 8 weeks (day 56) of the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of psychometric parameters - Change in Symptom Checklist 90 Scale (SCL-90) from baseline at 3 weeks and 8 weeks of the study.</measure>
    <time_frame>At day one, after 3 weeks (day 21), after 8 weeks (day 56) of the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive functions evaluation - California Verbal Learning Test (CVLT)</measure>
    <time_frame>At day one, after 8 weeks (day 56) of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive functions evaluation - Ruff Figural Fluency Test (RFFT)</measure>
    <time_frame>At day one, after 8 weeks (day 56) of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive functions evaluation - Stroop Test (A and B)</measure>
    <time_frame>At day one, after 8 weeks (day 56) of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive functions evaluation - Connecting Points Test (A and B)</measure>
    <time_frame>At day one, after 8 weeks (day 56) of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive functions evaluation - Attention and Perceptivity Test</measure>
    <time_frame>At day one, after 8 weeks (day 56) of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical analysis - morning cortisol level</measure>
    <time_frame>At day one, after 8 weeks (day 56) of the study</time_frame>
    <description>Biochemical analysis will be based on pro-inflammatory and anti-inflammatory cytokines measurements, morning cortisol concentration, tryptophan and its kynurenic pathway metabolites measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical analysis - cytokines measurements profile</measure>
    <time_frame>At day one, after 8 weeks (day 56) of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical analysis - kynurenic pathway metabolites measurements profile</measure>
    <time_frame>At day one, after 8 weeks (day 56) of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Depression</condition>
  <condition>Anxiety Disorder</condition>
  <arm_group>
    <arm_group_label>SSRI and probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and probiotic (Lactobacillus Plantarum 299v) to a group of patients diagnosed with depression (n=30).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SSRI and placebo of probiotic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and placebo of probiotic (crystalline cellulose powder) to a group of patients diagnosed with depression (n=30).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactobacillus Plantarum 299v</intervention_name>
    <description>Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.</description>
    <arm_group_label>SSRI and probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crystalline cellulose powder</intervention_name>
    <description>Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.</description>
    <arm_group_label>SSRI and placebo of probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>5-20mg daily</description>
    <arm_group_label>SSRI and probiotic</arm_group_label>
    <arm_group_label>SSRI and placebo of probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>50-100mg daily</description>
    <arm_group_label>SSRI and probiotic</arm_group_label>
    <arm_group_label>SSRI and placebo of probiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unipolar depression, with at least one depressive episode, present episode since at
             least 2 weeks, with Hamilton Depression Scale scoring 18 and higher with BMI =18,9 -
             29,9 kg/m2

        Exclusion Criteria:

          -  Inflammatory diseases eg. rheumatoid diseases, inflammatory bowel diseases,
             autoimmunological diseases

          -  Metabolic diseases e.g. diabetes type I,II, obesity (Body Mass Index)&gt;30 kg/m2

          -  Previously diagnosed other psychiatric diseases other than depression, psychoactive
             substances abuse, organic brain dysfunctions

          -  Smokers

          -  Patients after surgeries in last 3 months

          -  Oncological patients

          -  Patients during pregnancy or lactation

          -  Drugs which might influence measured parameters (e.g. lithium, antibiotics,
             glucocorticosteroids, antipsychotic drugs)

          -  Changes in routine blood biochemical parameters: morphology, electrolytes, Aspartate
             Aminotransferase (AST), Alanine Aminotransferase (ALT), creatinine, urea, C-reactive
             protein (CRP), thyroid-stimulating hormone (TSH).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leszek Z Rudzki, MD Psychiatry Specialist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry, Medical University of Bialystok</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Napoleon Waszkiewicz, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Psychiatry Department of Bialystok Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, Medical University of Bialystok</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2015</study_first_posted>
  <last_update_submitted>April 6, 2016</last_update_submitted>
  <last_update_submitted_qc>April 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>microbiota-gut-brain axis</keyword>
  <keyword>Lactobacillus Plantarum 299v</keyword>
  <keyword>probiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Serotonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

